Form 4: Neumora CEO Paul Berns Granted 1.65M Stock Options

Neumora Therapeutics' CEO and Chairman, Paul L. Berns, was granted 1,650,000 stock options with a $2.33 exercise price, vesting over four years.

Summary

• Paul L. Berns, the Chief Executive Officer and Chairman of the Board of Neumora Therapeutics, Inc. (NMRA), was granted 1,650,000 stock options.
• The stock options have an exercise price of $2.33 per share.
• The transaction date for this grant was January 8, 2026.
• The options have an expiration date of January 8, 2036.
• The vesting schedule dictates that 25% of the shares subject to the option vest on the first anniversary of January 8, 2026 (the "Vesting Commencement Date").
• Following the initial vesting, 1/48th of the total number of shares will vest monthly thereafter.
• All 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, which is January 8, 2030.
• Following this transaction, Paul L. Berns beneficially owns 1,650,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to the CEO is a standard executive compensation practice, aligning management's interests with long-term shareholder value. While it introduces potential future dilution, it generally reflects a commitment to the company's future performance and is a neutral to slightly positive event.

Positives

• The grant of stock options aligns the Chief Executive Officer's long-term financial interests with those of the shareholders, incentivizing performance and value creation.
• The multi-year vesting schedule encourages sustained commitment and long-term strategic focus from the CEO.

Negatives

• The grant introduces potential future dilution for existing shareholders if the options are exercised, increasing the total number of outstanding shares.

Risks

• The value of the stock options is subject to the future market price fluctuations of Neumora Therapeutics' common stock, meaning the options may not be in-the-money if the stock price does not rise above the exercise price.
• The vesting conditions require continued employment and achievement of potential performance milestones (though not explicitly stated as performance-based in this filing, typical for such grants), posing a risk to the executive if conditions are not met.
• Potential dilution from the exercise of these options could impact earnings per share for existing shareholders in the future.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's operational or financial performance. It solely reports an executive compensation transaction.

Industry Context

Executive stock option grants are a common form of compensation in the biotechnology and pharmaceutical industries, designed to incentivize long-term performance and align management interests with shareholder value creation. This practice is particularly prevalent in companies like Neumora Therapeutics, which are often in development stages with significant future growth potential tied to successful drug discovery and commercialization.

Comparison to Industry Standards

• Executive compensation packages, including stock option grants, vary widely across the biotechnology sector based on company stage, market capitalization, and executive experience.
• While the specific grant size of 1,650,000 options to a CEO is substantial, it is not uncommon for early-to-mid stage biotech companies like Neumora Therapeutics to use significant equity incentives to attract and retain top talent, especially given the long development cycles and inherent risks in drug discovery.
• Comparable companies often structure similar multi-year vesting schedules (e.g., 4-year vesting with a 1-year cliff) to ensure sustained commitment and align executive incentives with the company's long-term strategic goals.

Related Party Transactions

• Grant of 1,650,000 stock options to Paul L. Berns, the Chief Executive Officer and Chairman of the Board, as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also increased alignment of the CEO's interests with long-term shareholder value creation.
• Employees: Standard executive compensation practices can set a precedent for other employee incentive programs, potentially impacting morale and retention.

Next Steps

• Vesting of 25% of the granted options on January 8, 2027.
• Monthly vesting of 1/48th of the total shares thereafter.
• Full vesting of all granted options on January 8, 2030.

Key Dates

Keywords

Neumora Therapeutics, NMRA, Paul L. Berns, Stock Options, Executive Compensation, Insider Transaction, Form 4, CEO, Chairman, Biotechnology